Structure Therapeutics Inc. American Depositary Shares (GPCR)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the idea that a business must eventually produce cash. Structure Therapeutics does not yet. It is a clinical-stage biopharmaceutical company with 281 employees, and its lead candidate GSBR-1290 is an oral biased small molecule GLP-1 receptor agonist in two phase 2 trials for obesity, overweight, and related conditions. That is an interesting scientific bet, but it is not a proven business. There is no revenue in the filed figures, and losses are widening: net loss was $106.2 million in fiscal Q2 2026, the quarter ended 2026-06-30, versus $76.0 million in fiscal Q1 2026, the quarter ended 2026-03-31, and $61.7 million in fiscal Q2 2025, the quarter ended 2025-06-30. Full-year net loss was $141.2 million in FY2025, ended 2025-12-31, and $122.5 million in FY2024. Diluted EPS was -$0.49 in fiscal Q2 2026 and -$0.80 in FY2025. Trailing free cash flow is -$224.5 million, a -4.7% FCF yield. The balance sheet has no debt, D/E 0.00, and an Altman Z-score of 40.79, but the Piotroski F-score is 1/9, so accounting quality and momentum are weak. At the 2026-10-13 close of $22.31, FairStock's P/B is 1.17 and P/E is -7.36, which may look modest, but with ROE -20.21%, book value is mostly cash being consumed. FairStock score 52/100 and no Lynch category because it has lost money each of the last four years. Price is near the 52-week low of $22.10 and far from the high of $94.90. Without revenue or an approved product, there is no durable moat yet—only intellectual property and trial data. I would call this a speculative clinical option, not a value investment.

In plain English: Structure Therapeutics is a clinical-stage biotech developing oral medicines for obesity and related chronic diseases; it has no product revenue yet and loses money. The business looks weak on current financials because it has been unprofitable for years and spends heavily on drug trials. At the recent price it is not cheap based on profits—there are none—but it trades near its 52-week low and around its accounting value, so the value depends almost entirely on whether its lead drug succeeds.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer